The pace at which companies are integrating the sophisticated tools of artificial intelligence (AI) and machine learning (ML) into their drug discovery and development programs continues to accelerate.

Lantern Pharma Inc., a Dallas-based cancer medicines developer using a machine learning platform to accelerate its work, is raising $60 million through a public offering priced at $14 per share (NASDAQ:LTRN).